snk01
nkgen
['snk01', 'nkgen']
nkgen s parent company, nkmax, co., ltd., presented snk01 preclinical and phase i/iia clinical data at the 2023 american society of clinical oncology (asco) annual meeting. see press release at link below for more information. 
NKGen Biotech is restoring the full potential of the immune system
through Natural Killer cell immunotherapy